Electronic Xoft Intersociety Brachytherapy Trial
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The incidence of signs and symptoms of subcutaneous toxicities will be recorded at the following follow-up visits; six month, one year, two year, three year, four year, and five year.
5 years
No
Peter Beitsch, MD
Principal Investigator
Dallas Surgical Group
United States: Institutional Review Board
TPR-0186
NCT00742222
May 2008
January 2015
Name | Location |
---|---|
Florida Radiation Oncology Group | Orange Park, Florida 32073 |
DCH Cancer Treatment Center | Tuscaloosa, Alabama 35401 |
Cancer Institute of Cape Girardeau | Cape Girardeau, Missouri 63703 |
University of South Florida | Tampa, Florida 33612 |
Beth Israel | New York, New York 10003 |
Beverly Oncology | Montebello, California 90640 |
St Elizabeth's and Memorial Cancer Center | Swansea, Illinois 62226 |
Brockton Hospital Signature Health | Brockton, Massachusetts 02302 |
Shields Radiation Oncology | Quincy, Massachusetts 02619 |
AtlantiCare Cancer Care Institute | Galloway, New Jersey 08205 |
Nazha Cancer Center | Northfield, New Jersey 08225 |
Dallas Surgical Group / Northpoint Cancer Center | Dallas, Texas 75230 |